Here are the latest G-BA decisions from the G-BA meeting held on 2 October 2025 on the early benefit assessments of Jaypirca and Breyanzi.
A database of all previous G-BA resolutions is available in my store.
- Jaypirca (pirtobrutinib); new indication: Chronic lymphocytic leukemia (CLL), relapsed or refractory, monotherapy – Hint of minor additional benefit in one of three subgroups
- Breyanzi (lisocabtagene maraleucel); new indication: follicular lymphoma, after ≥ 2 prior therapies – Additional benefit not proven
Follow me on Instagram to never miss the latest G-BA decisions: